BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 19571477)

  • 1. Children's toxicology from bench to bed--Drug-induced renal injury (2): Nephrotoxicity induced by cisplatin and ifosfamide in children.
    Fujieda M; Matsunaga A; Hayashi A; Tauchi H; Chayama K; Sekine T
    J Toxicol Sci; 2009; 34 Suppl 2():SP251-7. PubMed ID: 19571477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early and late renal adverse effects after potentially nephrotoxic treatment for childhood cancer.
    Knijnenburg SL; Mulder RL; Schouten-Van Meeteren AY; Bökenkamp A; Blufpand H; van Dulmen-den Broeder E; Veening MA; Kremer LC; Jaspers MW
    Cochrane Database Syst Rev; 2013 Oct; (10):CD008944. PubMed ID: 24101439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early and late adverse renal effects after potentially nephrotoxic treatment for childhood cancer.
    Kooijmans EC; Bökenkamp A; Tjahjadi NS; Tettero JM; van Dulmen-den Broeder E; van der Pal HJ; Veening MA
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD008944. PubMed ID: 30855726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients.
    Rossi R; Gödde A; Kleinebrand A; Riepenhausen M; Boos J; Ritter J; Jürgens H
    J Clin Oncol; 1994 Jan; 12(1):159-65. PubMed ID: 8270973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prevention and management of nephrotoxicity from anti-cancer agents].
    Miyazaki J; Kawai K
    Nihon Rinsho; 2003 Jun; 61(6):973-7. PubMed ID: 12806945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective evaluation of ifosfamide-related nephrotoxicity in children and young adults.
    Ho PT; Zimmerman K; Wexler LH; Blaney S; Jarosinski P; Weaver-McClure L; Izraeli S; Balis FM
    Cancer; 1995 Dec; 76(12):2557-64. PubMed ID: 8625085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies to prevent nephrotoxicity of anticancer drugs.
    Skinner R
    Curr Opin Oncol; 1995 Jul; 7(4):310-5. PubMed ID: 7578377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticancer drug-induced kidney disorders.
    Kintzel PE
    Drug Saf; 2001 Jan; 24(1):19-38. PubMed ID: 11219485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cumulative prior dose of cisplatin as a cause of the nephrotoxicity of high-dose chemotherapy followed by autologous stem-cell transplantation.
    Caglar K; Kinalp C; Arpaci F; Turan M; Saglam K; Ozturk B; Komurcu S; Yavuz I; Yenicesu M; Ozet A; Vural A
    Nephrol Dial Transplant; 2002 Nov; 17(11):1931-5. PubMed ID: 12401849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ifosfamide nephrotoxicity in pediatric cancer patients.
    Lee BS; Lee JH; Kang HG; Hahn H; Lee JH; Shin HY; Ha IS; Cheong HI; Ahn HS; Choi Y
    Pediatr Nephrol; 2001 Oct; 16(10):796-9. PubMed ID: 11605785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal toxicity of cancer chemotherapeutic agents in children: ifosfamide and cisplatin.
    Jones DP; Chesney RW
    Curr Opin Pediatr; 1995 Apr; 7(2):208-13. PubMed ID: 7787938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide.
    Hartmann JT; Fels LM; Franzke A; Knop S; Renn M; Maess B; Panagiotou P; Lampe H; Kanz L; Stolte H; Bokemeyer C
    Anticancer Res; 2000; 20(5C):3767-73. PubMed ID: 11268452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term renal follow-up of children treated with cisplatin, carboplatin, or ifosfamide: a pilot study.
    McMahon KR; Harel-Sterling M; Pizzi M; Huynh L; Hessey E; Zappitelli M
    Pediatr Nephrol; 2018 Dec; 33(12):2311-2320. PubMed ID: 30218190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: relevance of age and dose as risk factors.
    Skinner R; Parry A; Price L; Cole M; Craft AW; Pearson AD
    Eur J Cancer; 2009 Dec; 45(18):3213-9. PubMed ID: 19850470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children.
    Loebstein R; Atanackovic G; Bishai R; Wolpin J; Khattak S; Hashemi G; Gobrial M; Baruchel S; Ito S; Koren G
    J Clin Pharmacol; 1999 May; 39(5):454-61. PubMed ID: 10234592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ifosfamide-induced nephrotoxicity in children: critical review of predictive risk factors.
    Loebstein R; Koren G
    Pediatrics; 1998 Jun; 101(6):E8. PubMed ID: 9606250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Refining therapeutic strategies for patients with resistant Wilm's tumor.
    Marina NM; Wilimas JA; Meyer WH; Jones DP; Douglass EC; Pratt CB
    Am J Pediatr Hematol Oncol; 1994 Nov; 16(4):296-300. PubMed ID: 7978044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective evaluation of high-dose ifosfamide-related nephrotoxicity in young adult patients with recurrent osteosarcoma previously treated with cisplatin, methotrexate and standard-dose ifosfamide.
    Ferrari S; Zolezzi C; Cesari M; Fasano MC; Lamanna G; Bacci G
    Anticancer Drugs; 1999 Jan; 10(1):25-31. PubMed ID: 10194544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic ifosfamide nephrotoxicity in children.
    Skinner R
    Med Pediatr Oncol; 2003 Sep; 41(3):190-7. PubMed ID: 12868118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal toxicity and chemotherapy in children with cancer.
    Ruggiero A; Ferrara P; Attinà G; Rizzo D; Riccardi R
    Br J Clin Pharmacol; 2017 Dec; 83(12):2605-2614. PubMed ID: 28758697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.